Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Huadong Pharma Signs $52 Million China Deal for Topical Psoriasis Therapy

publication date: Sep 5, 2023

Hangzhou Huadong Pharmaceutical continued its M&A activity by acquiring an exclusive license to market a topical psoriasis cream in Greater China that was developed by the UK’s MC2 Therapeutics. Huadong will make upfront and regulatory milestone payments of $16 million to MC2 and up to $36 million in sales-based milestones, plus royalties. The product, Wynzora cream, is a fixed-dose combination of calcipotriene and betamethasone dipropionate. Three weeks ago, Huadong in-licensed China-SE Asia rights to a topical steroid-free therapy for immune-mediated skin diseases from Arcutis, a Los Angeles biopharma, in a $94 million deal. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital